Search for: rheumatoid arthritis methotrexate autoimmune disease biomarker gene expression GWAS HLA genes non-HLA genes
| ID | PMID | Title | PublicationDate | abstract |
|---|---|---|---|---|
| 312886 | Radioimmune double PEG precipitation technique for detecting complexed IgE. | 1979 | The presence of IgE in immune complex-enriched fractions prepared by 3% polyethylene glycol (PEG) precipitation was studied. The dissolved PEG-insoluble fraction was incubated with [125I]anti-IgE antibodies an then precipitated again with 3% PEG. Radioactivity in the washed pellets was taken as indicating IgE present in immune complex form. A calibration curve was constructed using artificially prepared IgE-anti-IgE complexes. The method developed may be useful to detect other components present in immune complex fractions. | |
| 6271870 | Impaired regulation of Epstein-Barr virus-induced lymphocyte proliferation in rheumatoid a | 1981 Nov | The rate of outgrowth of EBV-infected B lymphocytes is regulated by normal T lymphocytes. Removal of T cells from normal whole lymphoid populations (PBM) markedly shortens the outgrowth time of the remaining B lymphocytes. There is little difference in the much more rapid outgrowth of rheumatoid PBM after the removal of T cells, which suggests that RA lymphoid cells are unable to regulate this process. To determine whether RA T cells are defective, or EBV-infected RA B cells are unresponsive to regulatory signals, EBV-induced outgrowth in autologous and allogeneic mixtures of RA and normal B and T cells was evaluated, employing morphologic criteria and 3H-thymidine incorporation. The difference in outgrowth between RA and normal PBM was reproduced by reconstitution of EBV-infected B cells with mitomycin-treated autologous T cells. In cell-mixing experiments, normal T cells appropriately regulated both normal and RA B cells similarly, whereas RA T cells were defective in regulating either B cell population. Thus, the rapid outgrowth of EBV-infected rheumatoid lymphoid cells is due to defective T cell regulation. Moreover, normal regulation does not require cell proliferation. | |
| 4071425 | [Use of high doses of glucocorticoids in patients with rheumatic diseases]. | 1985 | Short-term application of high doses of glucocorticoids removes the acuity of the generalized patterns of systemic rheumatic diseases. This is documented by the reported data and analysis of the authors' own 15 observations. The dose of glucocorticoids, duration of their application and administration routes are determined by the degree of the pathological process activity and by the organs concerned (kidneys, central nervous system). If the effect attained is doubtful, repeated courses of intensive treatment with glucocorticoids are indicated in some cases. | |
| 6697075 | Comparison of the analgesic effect of ten nonsteroidal anti-inflammatory drugs. | 1984 Feb | The analgesic effect of 10 anti-inflammatory drugs was compared using a single-blind method in 90 patients with rheumatoid arthritis. Each patient received two different drugs, for three days each and each drug was evaluated in 18 patients. After the trial, the patients considered which of the drugs they preferred. The greatest relief from pain was achieved by diclofenac, indomethacin, naproxen and tolfenamic acid, each of these being preferred by the majority of patients and being significantly (p less than 0.01) better than the least effective drugs ketoprofen and proquazone. Acetylsalicylic acid, azapropazone, carprofen and ibuprofen were considered intermediate in efficacy. | |
| 3924466 | Second line therapy in rheumatoid arthritis--a four year prospective study. | 1985 Jun | One hundred and twenty-three rheumatoid patients were commenced on one of the three second-line agents: sodium aurothiomalate (GST), penicillamine (P), or levamisole (L). After four years, 39% of the GST group, 20% of the penicillamine group, and 8% of the levamisole group remained on the original agent. Fifty five % of patients, however, were receiving some second-line agent at four years, and patients showed an improvement in inflammatory indices irrespective of whether or not they were still receiving second-line therapy. It is unclear whether this improvement reflects the natural history of the disease, or the fact that regular clinic attendance identifies patients who require further second-line therapy following cessation of the initial agent. | |
| 6278639 | [Psoriatic arthritis with renal amyloïdosis. A case-report. Review of the literature (aut | 1982 Mar 4 | A case of severe psoriatic arthritis with both spinal and peripheral joint involvement is reported. The patient, an HLA B27-positive man, was thirty-one years old at onset. Both antiinflammatory drugs and immunosuppressive agents (chlorambucil followed by azathioprine) were ineffective and the patient became bed-ridden. Thirty-three months after onset a severe nephrotic syndrome developed. Renal biopsy let to diagnosis of secondary renal amyloïdosis. The patient died five months later in spite of chemotherapy with melphalan and prednisone. Autopsy could not be performed. A review of the literature showed twelve other cases of psoriatic arthritis with secondary amyloïdosis. Men are affected more often than women. Twelve years was the average interval between onset of joint involvement and diagnosis of amyloïdosis. In three instances, however, this interval was less than thirtyeight months. Arthritis often included both spinal and peripheral joint involvement. Amyloïdosis was evidenced by a nephrotic syndrome in eight out of twelve cases. Prognosis is poor with a fourteen months average interval between onset of clinical amyloidosis and death. | |
| 3877983 | Pancytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid ar | 1985 Nov | Low dose pulse MTX was associated with the development of pancytopenia in six patients with RA. Two patients died. Factors implicated in the occurrence of this complication were renal impairment in five patients, medication errors by two patients, preexisting marrow injury from occult alcoholism in one patient, and an apparent idiosyncratic reaction to the drug in another. Medication errors were associated with the use of five or more medications, and the unusual schedule of administration of low dose MTX may also have been contributory. From a consideration of the clinical pharmacokinetics of MTX, we suggest other factors that may predispose to the occurrence of marrow toxicity: the presence of hypoalbuminemia, interactions between MTX and other protein bound or weakly acidic drugs, and the repetitive dosing schedule of low dose MTX. Based on our experience, patients with impaired renal function (creatinine greater than or equal to 2.0 mg/dL) should not receive MTX. Renal function should be monitored regularly during treatment with MTX, and blood counts should be observed carefully if a new drug is added or substituted. A 5 mg test dose of MTX before initiating weekly therapy may identify patients with severe hypersensitivity to the drug. The potential risks of using MTX in a patient unwilling to accept blood products should be acknowledged and discussed with the patient. Furthermore, we recommend the use of leucovorin if pancytopenia occurs, even if low or undetectable serum levels of MTX are present. | |
| 7342406 | Macular and paramacular detachment of the neurosensory retina associated with systemic dis | 1981 | We have reviewed 168 cases of angiographically proved SRD of the macular region of unknown etiology that were seen at The Cleveland Clinic Foundation. Thirty-seven percent of these patients had documented coincident systemic diseases. Of that group, patients with autoimmune disease appeared to have ocular symptoms during the active phase of the systemic illness. Nine cases are reported characterizing the coincidence of exacerbation of systemic disease with recurrent serous detachment of the neurosensory retina. It is our hypothesis that in patients with autoimmune disease, the choroiditis is secondary to the damage caused by immune complexes. Thus, in these patients, SRD was a manifestation of the systemic illness. | |
| 6789492 | Synoviorthesis versus synovectomy in the treatment of recurrent haemophilic haemarthrosis: | 1981 Apr 30 | The authors report a long-term evaluation of the effects of chemical and surgical synovectomies performed in two groups of patients which were comparable as regards number of haemarthrosis per year and joint mobility. The results obtained indicated that both synovectomy and synoviorthesis were effective in reducing the bleeding episodes; however, while synovectomy stopped almost completely the recurrence of haemarthrosis, synoviorthesis in 3 patients younger than 12 years did not modify it and in one case it even increased the bleeding tendency. Moreover, the occurrence of arthritic pain was observed in 6 knees treated by synoviorthesis and only in 3 knees treated by synovectomy. Finally, the joint function was significantly reduced in the synoviorthesis group as compared to the synovectomy group. In conclusion, synovectomy gave better results than synoviorthesis but the latter treatment has a number of economical and technical advantages and should therefore be considered in patients older than 12 year of age with good joint function and without evident radiological changes, in whom full dose replacement therapy has had no effect on the recurrence of haemarthrosis. | |
| 6307585 | Influence of plasma fibronectin on collagen cleavage by collagenase. | 1983 May | The influence of plasma fibronectin on the cleavage of interstitial collagen types I, II, and III by mammalian collagenase was investigated. To this end, rheumatoid arthritis synovial tissue collagenase was isolated from tissue culture supernatants. A highly active enzyme preparation was obtained. Different dilutions of the collagenase were incubated in tubes coated with [3H]-labeled collagens. Liberation of labeled fragments in the presence (200 micrograms per ml) or absence of fibronectin was measured at different time intervals (1-30 min). A significant inhibition of collagen degradation was observed in case of type I and type III collagens. Analogous experiments were carried out using collagen-coated tubes preincubated with fibronectin at a concentration of 200 micrograms/ml. Here, a strong inhibition (76 percent) of type III collagen digestion by collagenase was observed, while the cleavage of type I or type II collagen was completely unchanged after preincubation with fibronectin. A direct attack of the collagenase preparation on plasma fibronectin could be excluded in control digestion experiments using radioiodinated fibronectin as substrate. | |
| 6974746 | Immune complexes and autoantibodies in silicosis. | 1981 Oct | Serum specimens from 53 patients with silicosis were examined for the presence of antinuclear antibodies (ANA), rheumatoid factor (RF), immunoglobulins, and immune complexes. These humoral immunologic parameters were compared with radiographic changes and pulmonary function studies. A significant percentage of patients had an increased prevalence of ANA, RF, and immunoglobulin elevation (IgG, IgA). Immune complexes determined by the Raji-cell assay were detected in 31% of the patients. However, there was no significant correlation between any humoral immunologic abnormality and radiographic changes or declines in pulmonary function tests. These findings suggest that humoral immunologic abnormalities are not directly responsible for the lung changes in silicosis and cannot be used as "guides" to predict severity or progression of disease. | |
| 387372 | Naproxen up to date: a review of its pharmacological properties and therapeutic efficacy a | 1979 Oct | Naproxen is a propionic acid derivative with analgesic and anti-inflammatory activity which has been widely used in the treatment of rheumatic diseases. Naproxen has been well studied in rheumatoid arthritis and is as effective as aspirin but better tolerated, thus enabling more patients to continue with treatment. For this reason some clinicians now prefer to try propionic acid derivatives, such as naproxen, before aspirin in arthritic patients. In comparative studies with other non-steroidal anti-inflammatory drugs, such as indomethacin, ibuprofen, fenoprofen and others, all drugs were usually of similar overall efficacy although naproxen was sometimes preferred: but as with other non-steroidal anti-inflammatory agents, not all patients will respond to naproxen and in such cases other agents should also be tried until the most satisfactory drug is found for each patient. Naproxen is also effective in degenerative joint diseases of the hip and knee, although further well designed studies are needed to more clearly define its relative place compared with newer drugs such as diclofenac or diflunisal. Results of other comparative studies have shown that naproxen is a suitable alternative to phenylbutazone or indomethacin in ankylosing spondylitis and to aspirin in juvenile rheumatoid arthritis. Naproxen appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with pain following surgery or trauma and in pain of dysmenorrhoea. Naproxen has generally been better tolerated than aspirin or indomethacin at the dosages used. Because of its relatively long plasma half-life, naproxen can with convenieice be given twice daily, and there is some evidence that once daily dosage is as effective in rheumatoid arthritis. | |
| 6270783 | Measurement of soluble pyrophosphate in plasma and synovial fluid of patients with various | 1981 | Soluble pyrophosphate was measured in the plasma and synovial fluid of various groups of patients and in the plasma of two control groups. The two control groups consisted of 13 healthy subjects and 19 patients suffering from benign lumbar back pain. The other group of patients had rheumatoid arthritis (RA) (14 plasma and 19 synovial fluid examinations), osteoarthrosis (OA) (19 plasma and 26 synovial fluids) and articular chondrocalcinosis (ACC) (27 plasma and 43 synovial fluids). The level of soluble pyrophosphate in the plasma was 3.5 mumol/l in healthy subjects, 4.0 mumol/l in patients with lumbar back pain, 4.1 mumol/l in individuals having OA and 3.5 mumol/l in the group suffering from RA as well as for those with ACC. The differences between these values are not significant statistically. In the synovial fluid the values were 4.6 mumol/l for the group with RA, 12.7 mumol/l for those with OA and 34.2 mumol/l in the group having ACC. If a normal distribution of these values is assumed and the average values and standard deviations recalculated for each group after elimination of cases more than 3 standard deviations above the mean, then we obtain 9.8 mumol/l for the group with OA and 23.8 mumol/l for those with ACC. The difference between the group with RA and that with OA is highly significant (p greater than 0.0001). Even more significant is the difference between the group with RA and ACC (p less than 0.0005). The difference between the OA and the ACC is also highly significant (p less than 0.001). On the basis of these observations various mechanisms leading to the pyrophosphage crystal deposition disease are discussed. | |
| 6993666 | Crossover comparison of benoxaprofen and naproxen in rheumatoid arthritis. | 1980 | This multicenter double-blind clinical trial compared the efficacy and safety of benoxaprofen and naproxen in the treatment of rheumatoid arthritis. The studies followed a crossover design which provided 6 wk therapy with each of the 2 study drugs. Benoxaprofen at a single daily dose of 600 mg compared favorably to naproxen, 750 mg, administered in 2 equally divided doses. All efficacy results indicated slightly more improvement with benoxaprofen although the difference between the 2 drugs was not significant. Side effects were generally mild and only 1 patient discontinued benoxaprofen therapy because of a reactivation of a duodenal ulcer. | |
| 6402089 | HLA antigens and acetylcholine receptor antibodies in penicillamine induced myasthenia gra | 1983 Jan 29 | Antibodies to the acetylcholine receptor and HLA antigens have been studied in patients with myasthenia gravis occurring in association with penicillamine treatment. The properties of the antiacetylcholine receptor in these patients differed from those in patients with idiopathic myasthenia gravis in terms of specificity and affinity. These patients had an increased prevalence of HLA Bw35 and DR1 compared to controls and a decreased frequency of B8 and DR3 compared to patients with idiopathic myasthenia gravis. Likewise, they had a decreased frequency of DR4 compared to patients with rheumatoid arthritis. These data provide supportive evidence for a role for penicillamine in the induction of myasthenia gravis in genetically predisposed individuals. | |
| 3896258 | Performance characteristics of an enzyme-linked immunosorbent assay for the determination | 1985 | Some characteristics of an enzyme-linked immunosorbent assay for the determination of immunoglobulin M anti-Salmonella lipopolysaccharide antibodies have been assessed. Immunoglobulin M anti-lipopolysaccharide antibodies in serum samples from most patients with typhoid fever cross-reacted with S. typhimurium lipopolysaccharide. However, absorbance values with S. typhi lipopolysaccharide were always higher than with the heterologous antigens. Serum samples from two patients with S. paratyphi B infection failed to show significant immunoglobulin M binding to S. typhi lipopolysaccharide. Serum samples from six rheumatoid arthritis patients were negative in this immunoenzymatic assay with S. typhi or S. typhimurium lipopolysaccharide as coating antigen. Finally, interference by specific immunoglobulin G in the immunoglobulin M anti-S. typhi lipopolysaccharide antibodies determination was excluded. | |
| 6612199 | [Anti-collagen antibodies. Their detection in rheumatoid polyarthritis, chronic atrophic p | 1983 Jun | The authors administered by passive haemagglutination, natural or denatured type I and II anticollagen antibodies in the serum of 83 rheumatoid polyarthritis, 20 ankylosing spondylarthritis, 30 relapsing polychondritis, 13 diffuse sclerodermics, 12 Gougerot-Sjögren syndrome patients. Type II natural anti-collagen antibodies are common in relapsing polychondritis (37 percent). They are rarer in rheumatoid polyarthritis (15 percent) and the frequency is identical to that found in patients suffering from gonarthrosis and coxarthrosis. Natural type II anti-collagen antibodies may be occur in etiopathogenesis of relapsing polychondritis. Denatured II ant-collagen antibodies are common during ankylosing spondylarthritis (35 percent) and diffuse sclerodermia, and are found in rheumatoid polyarthritis (23 percent) and in Gougerot Sjögren syndrome (25 percent). They possibly play a pathological role in these diseases although this has not been proved. They are detected almost as often in the synovial fluid of inflammatory rheumatisms (53 percent) and in gonarthrosis (41 percent). | |
| 3968104 | Radiographic analysis of a low-modulus titanium-alloy femoral total hip component. Two to | 1985 Jan | We performed a detailed serial radiographic analysis of the femoral component of 323 cemented low-modulus titanium-alloy total hip prostheses. There was a low incidence of femoral component loosening as manifested by radiolucent zones at the stem-cement interface or cement fractures. There was also a low incidence of resorption of the calcar and cortical hypertrophy. Comparison of our data with those of others indicated that the incidence of loosening, calcar resorption, and cortical hypertrophy was usually lower than with similarly designed conventional high-modulus Charnley stems. These findings appear to support computer-modeling studies that have predicted a more even distribution of stresses along the entire length of the stem of the titanium-alloy prosthesis. Of the two configurations of femoral components used, the straight stems demonstrated a significantly lower incidence of radiographic evidence of loosening, calcar resorption, and cortical hypertrophy than the curved stems did. These findings have provided sufficient biomechanical rationale for the evolutionary development of the second-generation femoral components, which incorporate many features of the straight stem. | |
| 886226 | Serum 25-hydroxyvitamin D concentrations in patients receiving chronic corticosteroid ther | 1977 Aug | Serum 25-hydroxyvitamin D (25OHD) concentrations were measured by competitive protein-binding assay in 21 patients who were receiving chronic prednisone therapy and who demonstrated radiologic osteopenia. Results were compared to values obtained in 19 matched non-steroid-treated control subjects. Serum 25OHD values in control and steroid-treated subjects were virtually identical and showed a similar positive correlation with vitamin D intake. To rule out possible assay interference by postulated steroid-induced abnormal vitamin D metabolites, 25OHD was specifically isolated from pooled extracts of control and steroid-treatment patient sera by silicic acid column chromatography. 25OHD levels were again identical in both groups, and there was no evidence of radioassayable abnormal metabolites. It is concluded that the maintenance of normal serum levels of 25OHD is not altered by chronic moderate dose corticosteroid therapy. | |
| 4057204 | Gold induced aplastic anemia. Complete response to corticosteroids, plasmapheresis, and N- | 1985 Aug | A 47-year-old woman with rheumatoid arthritis (RA) had been treated with greater than 7 g of gold sodium thiomalate over a 5 year period when aplastic anemia developed. Treatment with corticosteroids, plasmapheresis and infusion of N-acetylcysteine (NAC) resulted in complete hematologic remission. Infusion of NAC increased daily urinary excretion of gold and use of an ambulatory infusion pump with a Hickman catheter allowed protracted outpatient infusion for more than 4 months' duration. It is now 20 months since the onset of aplastic anemia and she remains in complete hematologic remission. |